CELCライブシグナル | Getagraph.comで利益を最大化

買う 109557 min ago

@ $15.21

発行日: 13 2月 2024 @ 23:42

リターン: 9.07%

前回のシグナル: 2月 9 - 23:30

前回のシグナル: 売る

リターン: 3.75 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:35):

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States...

Stats
本日の出来高	144 176
平均出来高	227 324
時価総額	505.22M
EPS	$0 ( 2024-03-27 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.17
ATR14	$0.0640 (0.39%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Buller Richard E	Sell	350	Common Stock
2024-04-08	Buller Richard E	Buy	19 558	Stock Option (right to buy)
2024-04-08	Buller Richard E	Buy	12 654	Stock Option (right to buy)
2024-04-08	Buller Richard E	Buy	4 555	Stock Option (right to buy)
2024-04-08	Buller Richard E	Buy	2 310	Stock Option (right to buy)

INSIDER POWER
8.95
Last 100 transactions
Buy: 4 086 807 \| Sell: 2 961 808

ボリューム相関

長: -0.05 (neutral)

短: 0.88 (strong)

Signal:(49.255) Same movement expected

Celcuity Inc 相関

10 最も正の相関
ALKT	0.868
NNBR	0.864
DDI	0.861
AVDX	0.859
SPLK	0.856
TTSH	0.856
FCBC	0.852
BFI	0.85
ESQ	0.848
ADV	0.843

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Celcuity Inc 相関 - 通貨/商品

-0.76
( moderate negative )

-0.08
( neutral )

0.00
( neutral )

0.63
( weak )

0.93
( very strong )

0.64
( weak )

Celcuity Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-142 772 (0.00 %)
EPS:	$-2.69

FY	2023
収益:	$0
総利益:	$-142 772 (0.00 %)
EPS:	$-2.69

FY	2022
収益:	$0
総利益:	$-210 918 (0.00 %)
EPS:	$-2.68

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.88

Financial Reports:

No articles found.

Celcuity Inc

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.